Abstract
Introduction: Sézary Syndrome (SS) is an aggressively progressing and difficult to treat primary cutaneous T-cell lymphoma (CTCL). Prognosis is poor. Currently, cell surface expression of immune checkpoint relevant markers in SS is underreported. We aimed to evaluate the expression of BTLA, TIGIT, LAG-3, and FCRL3 on tumor T-cells and non-tumorous T-cells in the blood of SS patients, and compare it to its expression on T cells from healthy individuals.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
